单反相机镜头知识After having been stuck in a trading range, shares in Sanofi are returning to the lower bound of the range phase. This appears to be a good opportunity for opening new positions. Investors have an opportunity to buy the stock and target the € 87.6.单反相机镜头知识
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Sanofi accounts for 4.40 % of our European Portfolio. A trade is currently open since 06/10/2020 with a purchase price of € 90.28. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.
The share is getting closer to its long-term support in weekly data, at EUR 83.56, which offers good timing for buyers.
Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 82 support.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
For the past twelve months, EPS forecast has been revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The stock is in a well-established, long-term rising trend above the technical support level at 83.56 EUR
The group usually releases earnings worse than estimated.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.